A Clinical Trial of STP0404 in Treatment-Na ïve Adults With HIV-1 Infection
Condition: HIV-1-infection Interventions: Drug: Low-dose STP0404 (Pirmitegravir); Drug: Medium-dose STP0404 (Pirmitegravir); Drug: High-dose STP0404 (Pirmitegravir); Drug: Placebo Sponsor: ST Pharm Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 22, 2023 Category: Research Source Type: clinical trials
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
Condition: Advanced Solid Tumors Intervention: Biological: ASKG915 Sponsors: AskGene Pharma, Inc.; Jiangsu Aosaikang Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 22, 2023 Category: Research Source Type: clinical trials
A Clinical Trial of STP0404 in Treatment-Na ïve Adults With HIV-1 Infection
Condition: HIV-1-infection Interventions: Drug: Low-dose STP0404 (Pirmitegravir); Drug: Medium-dose STP0404 (Pirmitegravir); Drug: High-dose STP0404 (Pirmitegravir); Drug: Placebo Sponsor: ST Pharm Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 22, 2023 Category: Research Source Type: clinical trials
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
Condition: Advanced Solid Tumors Intervention: Biological: ASKG915 Sponsors: AskGene Pharma, Inc.; Jiangsu Aosaikang Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 22, 2023 Category: Research Source Type: clinical trials
A Clinical Trial of STP0404 in Treatment-Na ïve Adults With HIV-1 Infection
Condition: HIV-1-infection Interventions: Drug: Low-dose STP0404 (Pirmitegravir); Drug: Medium-dose STP0404 (Pirmitegravir); Drug: High-dose STP0404 (Pirmitegravir); Drug: Placebo Sponsor: ST Pharm Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 22, 2023 Category: Research Source Type: clinical trials
Bristol Myers Squibb ’s Investigational LPA1 Antagonist BMS-986278 Reduces the Rate of Lung Function Decline in Patients with Idiopathic Pulmonary Fibrosis
PRINCETON, N.J.--(BUSINESS WIRE) May 22, 2023 -- Bristol Myers Squibb (NYSE: BMY) today announced results from a Phase 2 study evaluating BMS-986278, a potential first-in-class, oral, lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 22, 2023 Category: Pharmaceuticals Source Type: clinical trials
Positive Results from Interim Analysis of'GEN-001' Plus avelumab (Bavencio) Phase II Trial
SEOUL, South Korea, May 19, 2023. Genome& Company a global leading microbiome therapeutics developer, announced that this phase II trial (NCT05419362) will continue without modifications to move on to the second stage, based on the... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 19, 2023 Category: Pharmaceuticals Source Type: clinical trials
Lilly's peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine
INDIANAPOLIS, May 18, 2023. The New England Journal of Medicine today published detailed results from Eli Lilly and Company ' s (NYSE: LLY) phase 2a study of peresolimab in rheumatoid arthritis (RA), in which peresolimab met the primary endpoint for... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 18, 2023 Category: Pharmaceuticals Source Type: clinical trials
Phase I Study of Safety and Pharmacokinetics of Topical Solution in Subjects With Androgenetic Alopecia
Condition: Androgenetic Alopecia Intervention: Drug: Minoxidil Sponsors: Aneira Pharma, Inc.; DataPharm Australia, CMAX Clinical Research, Agilex Australia Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 18, 2023 Category: Research Source Type: clinical trials
